Literature DB >> 312672

Characterization of lymphoblast Fc receptor expression in acute lymphoblastic leukemia.

G H Reaman, W J Pichler, S Broder, D G Poplack.   

Abstract

Lymphoblasts from 18 patients with untreated acute lymphoblastic leukemia were investigated for the presence of conventional cell surface markers (spontaneous sheep red blood cell rosette formation, complement receptors, and surface immunoglobulin). The expression of Fc receptors for both IgG and IgM was investigated using indicator bovine erythrocytes coated with rabbit anti-BRBC (IgG and LgM fractions). The leukemic cells of all patients in this tudy expressed Fc receptors for both IgC and LgM. In contrast with previous reports, null (non-T non-B) lymphoblasts as well as T lymphoblasts demonstrated Fc-IgG and Fc-IgM receptors. However, these two immunologic subclasses of leukemic cells demonstrated significantly different patterns of Fc receptor distribution. These data suggest that expression of Fc receptors is an early event in cellular differentiation in this lymphoid malignancy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 312672

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Characteristics and function of Fc receptors on human lymphocytes.

Authors:  P M Lydyard; M W Fanger
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

Review 2.  The T lymphoblastic malignancies.

Authors:  L M Nadler; E L Reinherz; S F Schlossman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

4.  Erythrophagocytosis by blasts in a case of de novo acute monoblastic leukemia with rare but characteristic t(8;16).

Authors:  A Gupta; G K Reddy; M Goyal; M R Kasaragadda
Journal:  J Postgrad Med       Date:  2017 Jul-Sep       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.